How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
33
IART Quote, Financials, Valuation and Earnings
Last price:
$11.16
Seasonality move
:
0.74%
Day range:
$10.70 - $11.29
52-week range:
$10.70 - $26.98
Dividend yield:
0%
P/E ratio:
70.14x
P/S ratio:
0.52x
P/B ratio:
0.84x
Volume:
776.1K
Avg. volume:
703.9K
1-year change:
-57.54%
Market cap:
$867.7M
Revenue:
$1.6B
EPS (TTM):
-$6.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
$429.6M | $0.80 | -2.94% | 217.65% | $15.50 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -57.02% | -40.33% | $12.2500 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
IRTC
iRhythm Holdings, Inc.
|
$201.8M | $0.06 | 21.21% | -49.15% | $220.60 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$277.2M | -$0.09 | 6.15% | -78.57% | $25.95 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
$11.14 | $15.50 | $867.7M | 70.14x | $0.00 | 0% | 0.52x |
|
CATX
Perspective Therapeutics, Inc.
|
$3.7900 | $12.2500 | $281.7M | -- | $0.00 | 0% | 256.98x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.26 | $14.20 | $168M | 31.59x | $0.00 | 0% | 1.24x |
|
IRTC
iRhythm Holdings, Inc.
|
$154.51 | $220.60 | $5B | -- | $0.00 | 0% | 6.99x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$19.76 | $25.95 | $1.3B | -- | $0.00 | 0% | 1.31x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.61 | $1.50 | $85.4M | 59.80x | $0.00 | 0% | 0.67x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
65.91% | 0.037 | 179.84% | 1.47x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
IRTC
iRhythm Holdings, Inc.
|
85.74% | 2.412 | 13.23% | 4.47x |
|
TNDM
Tandem Diabetes Care, Inc.
|
77.16% | 1.942 | 54.61% | 1.79x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
$226.1M | $25.9M | -14.85% | -37.15% | 6.43% | $25.8M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
IRTC
iRhythm Holdings, Inc.
|
$137.1M | -$4M | -6.2% | -54.18% | -2.08% | $20.1M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$134.3M | -$20.1M | -31.16% | -110.24% | -8.05% | $4.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Integra LifeSciences Holdings Corp. vs. Competitors
-
Which has Higher Returns IART or CATX?
Perspective Therapeutics, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -12425.36%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About IART or CATX?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 39.14%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.2500 which suggests that it could grow by 223.22%. Given that Perspective Therapeutics, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Perspective Therapeutics, Inc. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 CATXPerspective Therapeutics, Inc.11 1 0 -
Is IART or CATX More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.025, which suggesting that the stock is 2.536% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock IART or CATX?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or CATX?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.52x versus 256.98x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.52x 70.14x $402.1M -$5.4M CATXPerspective Therapeutics, Inc.256.98x -- $209K -$26M
-
Which has Higher Returns IART or INFU?
InfuSystem Holdings, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of 6.19%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About IART or INFU?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 39.14%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 71.91%. Given that InfuSystem Holdings, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe InfuSystem Holdings, Inc. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 INFUInfuSystem Holdings, Inc.5 0 0 -
Is IART or INFU More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.025, which suggesting that the stock is 2.536% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock IART or INFU?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or INFU?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while InfuSystem Holdings, Inc.'s PE ratio is 31.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.52x versus 1.24x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.52x 70.14x $402.1M -$5.4M INFUInfuSystem Holdings, Inc.1.24x 31.59x $36.5M $2.3M
-
Which has Higher Returns IART or IRTC?
iRhythm Holdings, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -2.7%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat iRhythm Holdings, Inc.'s return on equity of -54.18%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B IRTCiRhythm Holdings, Inc.71.09% -$0.16 $854.9M -
What do Analysts Say About IART or IRTC?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 39.14%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $220.60 which suggests that it could grow by 42.77%. Given that iRhythm Holdings, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe iRhythm Holdings, Inc. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 IRTCiRhythm Holdings, Inc.12 1 0 -
Is IART or IRTC More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.025, which suggesting that the stock is 2.536% more volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.075%.
-
Which is a Better Dividend Stock IART or IRTC?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or IRTC?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than iRhythm Holdings, Inc. quarterly revenues of $192.9M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than iRhythm Holdings, Inc.'s net income of -$5.2M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.52x versus 6.99x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.52x 70.14x $402.1M -$5.4M IRTCiRhythm Holdings, Inc.6.99x -- $192.9M -$5.2M
-
Which has Higher Returns IART or TNDM?
Tandem Diabetes Care, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -8.49%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B TNDMTandem Diabetes Care, Inc.53.88% -$0.31 $582.2M -
What do Analysts Say About IART or TNDM?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 39.14%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $25.95 which suggests that it could grow by 31.34%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Integra LifeSciences Holdings Corp. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 TNDMTandem Diabetes Care, Inc.7 13 0 -
Is IART or TNDM More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.025, which suggesting that the stock is 2.536% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.218%.
-
Which is a Better Dividend Stock IART or TNDM?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or TNDM?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.52x versus 1.31x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.52x 70.14x $402.1M -$5.4M TNDMTandem Diabetes Care, Inc.1.31x -- $249.3M -$21.2M
-
Which has Higher Returns IART or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of 3.93%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About IART or XTNT?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 39.14%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 145.9%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Xtant Medical Holdings, Inc. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is IART or XTNT More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.025, which suggesting that the stock is 2.536% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock IART or XTNT?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or XTNT?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Xtant Medical Holdings, Inc.'s PE ratio is 59.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.52x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.52x 70.14x $402.1M -$5.4M XTNTXtant Medical Holdings, Inc.0.67x 59.80x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Buy
62
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
60
JNUG alert for Jan 31
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
